On Thursday, Dermata Therapeutics Inc. (NASDAQ: DRMA) announced positive topline results from a cosmetic clinical study evaluating its recently launched skin renewal treatment, Tome Foundational Treatment.

Following the announcement, the stock jumped nearly 34%.

Study Findings Support Efficacy

The open-label study, which included 31 participants who applied the treatment once a week for four weeks, demonstrated improvements in various endpoints, including fine lines, hyperpigmentation, dark spots, smoothness, firmness, radiance, and overall appearance.

High Participant Satisfaction

Following four treatments, participants completed self-evaluations, with a significant majority expressing satisfaction.

Notably, 93% agreed the treatment was comparable to a professional in-office procedure, and 90% observed more noticeable results compared to other products.

The treatment was also well-tolerated, with no treatment-related adverse events reported.

Tome Foundational Treatment Availability

Tome Foundational Treatment is a once-weekly skincare product powered by Bioneedle, an ingredient derived from freshwater sponges.

It aims to renew the skin's appearance and enhance tone and texture over time. The product is currently available for purchase online.

In August, Dermata Therapeutics announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the company's Tome skincare brand.

Dermata Therapeutics Price Action

DRMA Price Action: Dermata Therapeutics shares were up 33.97% at $0.88 at the time of publication on Thursday, according to market data.